10-Q: Adaptive Biotechnologies Reports Q1 2026 Results, Revenue Up 35%

Adaptive Biotechnologies Corporation announced its first quarter 2026 financial results, showcasing a 35% year-over-year revenue increase driven by strong performance in its MRD business.

Summary

• Adaptive Biotechnologies Corporation reported first quarter 2026 revenue of $70.9 million, a 35% increase compared to $52.4 million in the first quarter of 2025.
• The company's net loss attributable to Adaptive Biotechnologies Corporation was $20.0 million for the quarter, an improvement from a net loss of $29.9 million in the prior year period.
• MRD revenue saw a significant increase of 53%, reaching $67.1 million, primarily driven by higher clonoSEQ test volumes and regulatory milestone revenue.
• Immune Medicine revenue decreased by 57% to $3.8 million, largely due to the termination of the Genentech Agreement.
• Operating expenses increased to $90.1 million from $82.0 million, with notable increases in sales and marketing, and general and administrative expenses.
• Cash, cash equivalents, and marketable securities stood at $221.9 million as of March 31, 2026, providing sufficient liquidity for at least the next 12 months.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth and improved net loss, although the decline in the Immune Medicine segment warrants monitoring.

Positives

• Total revenue increased by 35% to $70.9 million for the three months ended March 31, 2026, compared to $52.4 million for the same period in 2025.
• MRD revenue grew by 53% to $67.1 million, driven by a 41% increase in clonoSEQ test volume to 32,595 tests.
• Regulatory milestone revenue within the MRD segment doubled to $9.0 million.
• Net loss attributable to Adaptive Biotechnologies Corporation improved to $20.0 million from $29.9 million in the prior year period.
• Adjusted EBITDA showed a significant improvement, moving from a deficit of $12.7 million to $2.5 million.
• The company maintains a strong liquidity position with $221.9 million in cash, cash equivalents, and marketable securities.

Negatives

• Immune Medicine revenue decreased by 57% to $3.8 million, primarily due to the termination of the Genentech Agreement.
• Operating expenses increased by 10% to $90.1 million, with sales and marketing expenses up 14% and general and administrative expenses up 21%.
• Despite revenue growth, the company still reported a net loss of $20.0 million.
• The company's accumulated deficit stands at $1.4 billion as of March 31, 2026.

Risks

• The company's ability to leverage and extend its immune medicine platform for product discovery, development, and commercialization.
• Achieving and maintaining commercial market acceptance for current and future products and services, including coverage and reimbursement decisions.
• Realizing payments such as milestone fees based on customers' use of data for their research or regulatory goals.
• Understanding T-cell mediated responses across different indications and developing products using TCR-antigen binding data.
• Reliance on collaborators and third parties for development, clinical testing, and regulatory approval, which may fail at any time.
• Potential for future capital raises which may result in dilution to shareholders.
• The risk of future ownership changes limiting the utilization of Net Operating Loss (NOL) carryforwards.

Future Outlook

The company expects its MRD revenue to increase in both the short and long term due to enhanced penetration in existing patient populations, expansion into new populations, and optimized payor coverage. Immune Medicine revenue is expected to increase in the short term. Cost of revenue is expected to moderately increase in the short term and increase in absolute dollars long term, with a decrease in cost per sample over the long term due to efficiencies. Research and development expenses are expected to moderately decrease in the short term and decrease as a percentage of revenue in the long term. Sales and marketing expenses are expected to moderately increase in the short term and increase in absolute dollars long term, but decrease as a percentage of revenue. General and administrative expenses are expected to moderately decrease in the short term and decrease as a percentage of revenue in the long term. The company believes its existing cash, cash equivalents, and marketable securities will be sufficient to fund operations through at least the next 12 months.

Management Comments

• We are advancing the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.
• Our existing and future commercial products and services are aligned to two business areas which we refer to as MRD and Immune Medicine.
• We believe our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12 months.

Industry Context

StockSavvy.ai notes that Adaptive Biotechnologies' performance in the first quarter of 2026 highlights a bifurcated business performance, with strong growth in its MRD segment contrasting with a decline in its Immune Medicine segment. This trend reflects the broader industry's focus on diagnostics and targeted therapies, where specialized platforms like clonoSEQ are gaining traction, while early-stage research and licensing revenues can be more volatile.

Comparison to Industry Standards

• The 35% year-over-year revenue growth for Adaptive Biotechnologies in Q1 2026 is robust compared to the average revenue growth of many established diagnostic and biotechnology companies, which often see single to low double-digit growth.
• The increase in clonoSEQ test volume by 41% indicates strong market adoption, potentially outpacing the growth rates of similar diagnostic tests in areas like oncology and immunology.
• The company's net loss of $20.0 million, while significant, represents an improvement from the prior year, aligning with the typical investment cycles in the biotech sector where R&D and commercialization efforts often precede profitability.
• The significant revenue contribution from the MRD segment (95% of total revenue in Q1 2026) suggests a successful commercialization strategy for this specific diagnostic, which is a key benchmark for companies in the precision medicine space.

Legal Proceedings

• The company is not currently a party to or aware of any proceedings that are believed to have a material adverse effect on its business, financial condition, or results of operations.

Stakeholder Impact

• Shareholders: Potential dilution if future capital raises occur; improved financial performance may lead to increased stock value.
• Employees: Continued investment in R&D and commercialization may lead to growth opportunities; share-based compensation remains a significant expense.
• Customers: Continued development and expansion of clonoSEQ and other diagnostic/research services.
• Payors: Ongoing efforts to secure and optimize coverage and reimbursement rates for clonoSEQ.
• Creditors: No significant debt disclosed beyond the revenue interest purchase agreement, suggesting limited direct impact.

Next Steps

• Continue to increase MRD clinical testing volume through enhanced penetration in existing covered patient populations.
• Expand into new patient populations for MRD testing.
• Optimize payor coverage for MRD testing.
• Continue research and development initiatives related to mapping TCRs to antigens.
• Advance target discovery capabilities.
• Utilize existing cash, cash equivalents, and marketable securities to fund commercial and assay development initiatives associated with clonoSEQ.
• Continue to monitor for changes that could trigger limitations on NOL carryforwards.

Key Dates

Recommendation

The company shows strong revenue growth in its core MRD business and improved financial metrics, but the decline in the Immune Medicine segment and continued net losses suggest a cautious approach. While the positive trends are encouraging, further sustained growth and profitability are needed to warrant a stronger recommendation.

Keywords

Adaptive Biotechnologies, 10-Q, MRD, Immune Medicine, clonoSEQ, Revenue, Net Loss, Financial Results, Biotechnology, Healthcare